Western New York BloodCare, Buffalo
Northwell Health Hemostasis and Thrombosis Center at Long Island Jewish and Cohen Children's Medical Center, Hyde Park
Weill Cornell Medical College - New York Presbyterian Hospital, New York
ir dar 2

Renkami dalyviaiStebimasis tyrimas

Visi amžiai · Visoms lytims · Atnaujinta 2026-08-17 · NCT04398628

Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

Mount Sinai Medical Center, New York
Jacobi Medical Center, The Bronx

Renkami dalyviai2 fazė

Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-08-14 · NCT06699849

Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

Jacobi Medical Center, The Bronx

Renkami dalyviai2 fazė

Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-05 · NCT07224360

The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

Richmond University Medical Center- Site Number : 8400038, Staten Island
Montefiore Medical Center - Moses Campus- Site Number : 8400057, The Bronx

Renkami dalyviai3 fazė

Amžius nuo 10 iki 65 · Visoms lytims · Atnaujinta 2026-07-29 · NCT06975865

Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease

New York Medical College, Valhalla

Renkami dalyviai2 fazė

6 Months – 21 Years · Visoms lytims · Atnaujinta 2026-07-27 · NCT02675959

Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease

Columbia University Irving Medical Center, New York
Memorial Sloan Kettering, New York

Renkami dalyviai1/2 fazė

Amžius nuo 12 iki 50 · Visoms lytims · Atnaujinta 2026-07-02 · NCT04819841

131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)

Columbia University Irving Medical Center, New York

Renkami dalyviai1 fazė

Amžius nuo 12 iki 50 · Visoms lytims · Atnaujinta 2026-06-10 · NCT07015684

Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease

Roswell Park (MRD-HCT), Buffalo
Columbia Presbytarian (NT-DMT), New York
Cohen's Children Hospital (NT-DMT), Queens
ir dar 4

Renkami dalyviaiStebimasis tyrimas

Amžius nuo 3 iki 20 · Visoms lytims · Atnaujinta 2026-06-04 · NCT06941389

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Memorial Sloan Kettering Suffolk - Commack (Consent only), Commack
Memorial Sloan Kettering Westchester (Consent only), Harrison
Memorial Sloan Kettering Nassau (All protocol activities), Rockville Centre

Renkami dalyviai2 fazė

Amžius nuo 2 iki 50 · Visoms lytims · Atnaujinta 2026-06-03 · NCT05736419

Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

New York Presbyterian Hospital - Morgan Stanley Children's Hospital, New York

Renkami dalyviai3 fazė

Amžius nuo 12 iki 35 · Visoms lytims · Atnaujinta 2026-03-23 · NCT05477563

Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease

Columbia University, New York

Renkami dalyviai2 fazė

Amžius nuo 2 iki 25 · Visoms lytims · Atnaujinta 2026-03-10 · NCT03587272

A Long-term Follow-up Study in Patients Who Received BEAM-101

Columbia University Irving Medical Center, New York

Renkami dalyviaiStebimasis tyrimas

Amžius nuo 14 iki 37 · Visoms lytims · Atnaujinta 2026-01-28 · NCT07373639

Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain

Weil Cornell Medical College, New York
University of Rochester Medical Center, Rochester

Renkami dalyviai

Amžius nuo 16 iki 30 · Visoms lytims · Atnaujinta 2026-01-07 · NCT06374238

Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain

Mount Sinai Hospital, New York

Renkami dalyviai2 fazė

Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-10-02 · NCT05519111

AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion

New York Medical College, Valhalla

Renkami dalyviai2 fazė

1 Day – 30 Years · Visoms lytims · Atnaujinta 2025-08-08 · NCT04099966

Cannabidiol in Sickle Cell Disease

Icahn School of Medicine at Mount Sinai, Manhattan

Renkami dalyviai1/2 fazė

Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-06-25 · NCT06930703

Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.